Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn

Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases

(2017) Taku Fukuzawa et al.   Scientific Reports

Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics

(2016) Danlin Yang et al.   ANALYTICAL BIOCHEMISTRY

PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody–antigen binding model

(2016) Kenta Haraya et al.   Drug Metabolism and Pharmacokinetics

 De novoisolation of antibodies with pH-dependent binding properties

(2015) Pauline Bonvin et al.   mAbs

Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates

(2015) Andrew E. Nixon et al.   Frontiers in Immunology

pH-dependent antigen-binding antibodies as a novel therapeutic modality

(2014) T. Igawa et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling

(2014) M. Jack Borrok et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery

(2014) E-Chiang Lee et al.   NATURE BIOTECHNOLOGY

The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics

(2013) Siva Charan Devanaboyina et al.   mAbs

Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo

(2013) Tomoyuki Igawa et al.   PLoS One

Evaluation of a Catenary PBPK Model for Predicting the In Vivo Disposition of mAbs Engineered for High-Affinity Binding to FcRn

(2012) Yang Chen et al.   AAPS Journal

A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics

(2012) Peter Hodsman et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9

(2012) Javier Chaparro-Riggers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Extensive quantitative remodeling of the proteome between normal colon tissue and adenocarcinoma

(2012) Jacek R Wiśniewski et al.   Molecular Systems Biology

Bioanalytical Approaches to Quantify “Total” and “Free” Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development

(2011) Jean W. Lee et al.   AAPS Journal

Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human

(2011) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Pharmacokinetics of Anti-hepcidin Monoclonal Antibody Ab 12B9m and Hepcidin in Cynomolgus Monkeys

(2010) Jim J. Xiao et al.   AAPS Journal

Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets

(2010) Jasmine P. Davda et al.   mAbs

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

(2010) Tomoyuki Igawa et al.   NATURE BIOTECHNOLOGY

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma

(2009) Philip J. Lowe et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY